Technologieangebote

Cachexia related to cancer, occurs in 30-70% of cancer patients and still represents an as-yet non-curable and fatal paraneoplastic syndrome in a variety of tumor entities. The present invention discloses a new method for preventing cancer cachexia based on preventing inhibition of the protein AMPK.

6% of all prostate cancer patients die due to their illness. However, 80% of all prostate cancer patients do not need therapy, since their cancers grow slowly. Since the mainly used marker (prostate-specific antigen, PSA) is also elevated in case of inflammatory processes or with benign prostatic hyperplasia, DKFZ inventors analysed serum samples and identified miRNA-375 and miRNA-141 as new biomarkers for high-risk tumors.

DKFZ researchers identified nuclear receptor tailles (Tlx) as a valuable drug target for brain tumors especially gliobastomas. In vivo experiments showed almost doubling in survival time of mice harbouring brain tumors by inhibiting the expression of Tlx in tumor cells. In addition a highly significant correlation between expression of Tlx in brain tumor cells and survival of the patient was demonstrated.

The novel combined power-to-gas & Biogas upgrading Technology is producing high-purity methane, carbon dioxide and water in a single membrane separation system.

Device and method to coat particles and powdres of any size and shape by magnetron sputtering. Even particles <1 μm can be coated and film thicknesses from 0.1 to 100 nm achieved. Use of metal or compound materials for adhesive, wear resistant, conductive and catalytic coatings.

A new and convenient synthesis method has been developed for coupling a ligand (e.g. PEG, peptides) through a cleavable disulfide linkage to an oligonucleotide at the 2´ position of a ribose ring. The resulting oligonucleotide conjugates are taken up efficiently into cells without the need for a transfection agent, and the 2´ OH group modification has
a positive impact on stability, allowing natural (phosphodiester) oligonucleotide sequences to be used. Preliminary in vitro experiments have demonstrated effective target gene down-regulation.